tachycardia
TACHYCARDIA

Tachycardia or tachyarrhythmia is used to describe the presence of cardiac rhythm abnormality in states when cardiac rate is increased to >100 bpm.

Divided into supraventricular and ventricular tachycardia.

Signs and symptoms related to rapid heart rate are altered sensorium, angina, shortness of breath, myocardial infarction, hypotension and other signs of shock (eg cold clammy skin, low urine output), heart failure or pulmonary congestion.

Introduction

  • Ventricular tachycardia is more common in patients with a history of cardiac disease
  • Atrioventricular nodal reentrant tachycardia (AVNRT) is more common in women than in men
  • In adolescents, AVNRT and atrioventricular reentrant tachycardia (AVRT) are more prevalent
  • Use of the accessory pathway for tachycardia is more frequent in younger population and decreases with age

Definition

  • Used interchangeably with tachyarrhythmias, used to describe the presence of cardiac rhythm abnormality in states when cardiac rate is increased to >100 beats per minute (bpm)

Signs and Symptoms

Serious signs and symptoms are often demonstrated at ventricular rates >150 bpm

Signs and symptoms related to rapid heart rate (HR):

  • Altered sensorium
  • Angina
  • Hypotension
  • Shirt flapping/neck pulsations (more common in AVNRT)
  • Polyuria (more common in AVNRT)
  • Other signs of shock (eg cold clammy skin, low urine output), heart failure (HF) or pulmonary congestion
  • Shortness of breath
  • Myocardial infarction (MI)
  • Palpitations
  • Syncope, lightheadedness

Risk Factors

  • Hypertension
  • Diabetes mellitus (DM)
  • Obesity
  • Smoking
  • Increasing age
  • Valvular heart disease
  • Heart failure
  • Myocardial infarction
  • Cardiothoracic surgery
  • Excessive alcohol intake
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
New drug applications approved by US FDA as of 01 - 15 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.